Latest news with #Eylea
Yahoo
2 days ago
- Business
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest's Substack. In this article, we will summarize the bulls' thesis on REGN. Regeneron Pharmaceuticals, Inc. (REGN)'s share was trading at $605.39 as of 29th May. REGN's trailing and forward P/E were 15.39 and 17.39 respectively according to Yahoo Finance. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Regeneron's latest earnings report was notably weak, with a 3.7% revenue decline and a 14% EPS drop, surprising given the company's history of exceeding market expectations. The primary driver was a steep 26% year-over-year decline in the U.S. Eylea franchise, particularly a 39% drop in 2mg Eylea sales. This was partly due to a co-pay assistance funding gap, which forced many Medicare patients to switch to cheaper alternatives like compounded Avastin, impacting both Regeneron and rival Roche's Vabysmo. Regeneron, having contributed over $400 million last year to charitable foundations supporting co-pay assistance, is now seeking to share this burden, proposing a matching donation program to encourage broader industry support. Another setback was the FDA's Complete Response Letter delaying approval of the Eylea-HD pre-filled syringe, a key product needed to compete with Vabysmo. The delay stemmed from third-party component issues rather than drug efficacy, and management believes resolution could be near. Margins also contracted, with gross margin falling from 89% to 85% due to unspecified inventory write-offs, possibly related to older Eylea 2mg or even leftover REGEN-COV stock. However, the margin pressure appears more tied to one-offs and increased R&D spending than structural issues. On a more positive note, Regeneron's pipeline is broadening meaningfully. Itepekimab, an IL-33 antibody, shows promise as a major respiratory asset with pivotal COPD data upcoming and expanded trials underway. The growing RNAi pipeline, now at nine siRNAs through its Alnylam collaboration, signals Regeneron's potential evolution beyond antibodies into a broader genetic medicine powerhouse. Regeneron Pharmaceuticals, Inc. (REGN) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held REGN at the end of the first quarter which was 68 in the previous quarter. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau. Per the terms of the agreement, Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achievement of development, regulatory and sales milestones. Any royalties on global net sales in the future (outside the designated territories) would be in the low double digits. HS-20094 has been evaluated in over 1,000 patients and administered as a weekly subcutaneous injection. The candidate has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist. The candidate is currently being evaluated in a phase III study in obesity in China, and a phase IIb study in diabetes is ongoing. The in-licensing agreement for an obesity candidate will expand REGN's obesity pipeline, which includes trevogrumab. Regeneron recently announced positive interim results from the ongoing phase II COURAGE study investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity. COURAGE was designed to investigate the quality of weight loss in patients with obesity. Results showed that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass. Garetosmab is being evaluated for the treatment of fibrodysplasia ossificans progressive. The successful development of any obesity treatment will be a great boost for the company. We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi SNY reported results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD). While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same. REGN and SNY are currently reviewing the data and plan to discuss the next steps with regulatory authorities. Year to date, REGN's shares have lost 31.7% compared with the industry's 3.2% decline. Image Source: Zacks Investment Research Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line. Eylea sales have been under pressure for some time now due to competition from Roche's Vabysmo. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line. Apart from Eylea, profits from the sales of asthma drug Dupixent are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for Dupixent. While the obesity market is lucrative, REGN is a pretty late entrant here. The market is dominated by bigwigs like Novo Nordisk NVO and Eli Lilly LLY. The stupendous success of Novo Nordisk's obesity drug, Wegovy (semaglutide) and Eli Lilly's Zepbound has prompted many companies to join the bandwagon. Buoyed by this success, both Lilly and NVO have taken significant strides in developing their obesity portfolios further. Given the significant market potential of obesity, other players are also striving to grab a chunk of this pie. Regeneron currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Forbes
6 days ago
- Business
- Forbes
REGN Stock Undervalued At $500?
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion. This recent occurrence has intensified the existing pressures on REGN stock. At present, trading at $490, the stock has decreased 60% from its 52-week peak of about $1,200. A large portion of this downturn can be ascribed to the company's less-than-expected performance, especially concerning its existing blockbuster treatment, Eylea. To add to Regeneron's challenges, the U.S. Food and Drug Administration (FDA) recently rejected a pre-filled syringe variant of Eylea HD, citing problems with a third-party supplier. In light of the significant drop in Regeneron's stock price, a natural question emerges: is REGN now a viable buying opportunity? From a valuation standpoint, the stock seems undervalued, indicating an attractive entry point for investors. We believe there is little reason for long-term concern with REGN stock, rendering its current valuation notably low. Our conclusion is derived from a thorough analysis that compares REGN's current valuation with its recent operating performance and historical financial health. Our evaluation of Regeneron Pharmaceuticals across essential parameters—Growth, Profitability, Financial Stability, and Downturn Resilience—suggests that the company continues to exhibit a very strong operational performance and financial condition, as elaborated further below. Nevertheless, for investors seeking lower volatility than that of individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and delivered returns exceeding 91% since its inception. Additionally, see – Buy, Sell, or Hold HIMS Stock? When considering the cost per dollar of sales or profit, REGN stock appears slightly undervalued compared to the broader market. Regeneron Pharmaceuticals' Revenues have seen a slight decline over recent years. Regeneron Pharmaceuticals' profit margins are significantly higher than those of most companies in the Trefis coverage universe. Regeneron Pharmaceuticals' balance sheet appears very robust. REGN stock has experienced an impact that was slightly better than the benchmark S&P 500 index during various recent downturns. Concerned about the influence of a market crash on REGN stock? Our dashboard – How Low Can Regeneron Pharmaceuticals Stock Go In A Market Crash? – includes a comprehensive analysis of the stock's performance during and after past market crashes. In conclusion, Regeneron Pharmaceuticals' performance across the mentioned parameters is summarized as follows: Regeneron has demonstrated strong performance across crucial financial metrics, and we contend this is not fully captured in its current stock valuation, which renders it an attractive investment. This substantiates our assertion that REGN is a stock worth buying. The recent clinical trial setback for itepekimab will most likely postpone its launch, as the drug will require further trials. Nevertheless, Regeneron stands to gain significantly from the strong growth of Dupixent, a drug created in partnership with Sanofi. Dupixent's sales rose 19% to $3.7 billion last quarter, with potential peak annual sales surpassing $20 billion. Furthermore, Regeneron has a promising pipeline with over a dozen programs currently in late-stage trials, suggesting future growth opportunities. Even though a setback in a clinical trial and declining Eylea sales may logically lead to a compression in valuation multiples, we believe the selling pressure on REGN stock at values below $500 is excessive. We think investors can exploit this current dip as a buying chance for strong long-term gains. Nevertheless, prior to making any investment choices, it's critical to consider the associated risks. Any adverse outcomes from ongoing clinical trials, particularly related to its COPD treatment, could result in further declines in the stock. Moreover, during periods of broader market downturns stemming from macroeconomic uncertainties, REGN stock could also decrease. Although Regeneron has historically outperformed the broader market during certain recent corrections, it remains susceptible to sharp declines. Separately, see – Plug Power's Hydrogen Hopes Dashed? While REGN stock appears promising, investing in a single stock can present risks. Conversely, the Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, has a history of consistently outperforming the S&P 500 over the past 4 years. Why is that? Collectively, HQ Portfolio stocks have delivered better returns with less risk compared to the benchmark index; presenting less volatility, as demonstrated in HQ Portfolio performance metrics.
Business Insider
31-05-2025
- Business
- Business Insider
Regeneron price target lowered to $645 from $686 at Leerink
Leerink lowered the firm's price target on Regeneron (REGN) to $645 from $686 and keeps an Outperform rating on the shares. In the wake of itepekimab's failure in one of two Phase 3 COPD trials, the firm is removing the drug from its model and lowering its price target on the shares, the analyst tells investors in a research note. The firm noted that its investment thesis is that Regeneron shares can outperform from current levels because it expects growth to accelerate after a big Eylea sales/earnings stepdown in 2025; pipeline newsflow is likely to improve after several months of disappointing press releases, and; shares are trading near historical low multiple levels. The company should return to growth in 2026 and accelerate in 2027, the analyst adds. Confident Investing Starts Here:
Yahoo
30-05-2025
- Business
- Yahoo
RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results
Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29. The rating comes as Regeneron awaits the findings of a phase III study on the medication candidate itepekimab, which is intended to treat chronic obstructive pulmonary disease (COPD). Based on a thorough analysis of preclinical and clinical data for COPD biologics, Abrahams expressed hope over itepekimab's potential to reduce episodes of COPD drastically. He estimates an unadjusted global peak revenue of $6 billion and believes that favorable study results could open up a sizable market opportunity. According to the analyst, there is a 65% possibility that Regeneron's stock would rise by 5–15% as a result of the upcoming itepekimab data. Additionally, he asserts that positive results from the itepekimab trials and other pipeline outcomes would divert investors' attention from worries about the depletion of Regeneron's other medicine, Eylea. While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
